Ipca Laboratories Secures Global Licensing for Subcutaneous Biologics Technology

Ipca Laboratories signed a global licensing agreement with Bhami’s Research Laboratory for its proprietary subcutaneous biologics delivery platform. Ipca will develop and commercialize monoclonal antibodies for oncology and inflammatory diseases. BRL will receive milestone fees for technology transfer and royalties on future global net sales upon commercialization.